Pioneering the Future of Allergy Treatment
Food allergies affect more than 30 million people nationwide, with peanut allergy alone impacting over 1.5 million. Auni Therapeutics is developing a next-generation immunotherapy for food allergies, with a platform designed to expand across multiple allergens and deliver durable clinical benefits.
Our bold vision
Create a world where severe food allergies are no longer life-threatening.
Who We Are
Auni Therapeutics is led by a multidisciplinary executive team that combines deep clinical expertise with a proven ability to build and commercialize high-value biotech assets. Our leadership spans pioneering clinical innovation, disciplined execution, and a track record of raising significant capital and delivering successful strategic outcomes. We are physician-scientists, serial entrepreneurs, and operational leaders focused on translating next-generation immunology into durable therapeutic assets and investor returns.